Effective symptomatic treatment and reduction of influenza viral load in children by nasal - spraying Bacillus spore probiotics (LiveSpo Navax)

Abstract

The influenza virus is a common cause of respiratory tract infections, and treatment of the disease remains symptomatic reduction. We conducted a randomized and blind clinical trial to investigate the symptomatic treatment effects of LiveSpo® Navax containing > 5 billion Bacilus spores in children with acute respiratory diseases caused by the influenza virus at the Vietnam National Children’s Hospital. A total of 30 influenza-infected patients (n = 15/ group x 2 groups: Navax and Control) were sprayed into their noses 3 times per day in conjunction with standard hospital drug therapy. As a result, recovery time for fever and nasal secretion in the Navax group were 1 - 2 day shorter than the control group, equivalent to
about 53 - 90% higher effects obtained in Navax group than in the control group. After 2 days of treatment, the Navax group had about a 900-fold reduction, which was 60-fold more effective than the control group (the control group had a 15-fold reduction). The Navax group showed no signs of abnormal breath nor irritation of the nasal mucosa. This primary clinical study demonstrates the safety, symptomatic-reduction, and viral load-lowering effects of Bacillus spore probiotics as nasal sprays in children infected with the influenza virus.